Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
Authors:
- 1 January 2022
- journal article
- research article
- Published by Elsevier in The Lancet Gastroenterology & Hepatology
- Vol. 7 (1) , 17-27
Abstract
No abstract availableKeywords
Funding Information
- Roche
- F. Hoffmann-La Roche
This publication has 20 references indexed in Scilit:
- Overcoming Disease-Specific Matrix Effect in A Clinical Pharmacokinetic Assay Using A Microfluidic Immunoassay TechnologyBioanalysis, 2017
- Ulcerative colitisThe Lancet, 2017
- Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to InfliximabJournal of Crohn's and Colitis, 2016
- Long-term outcomes of colectomy surgery among patients with ulcerative colitisSpringerPlus, 2015
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trialThe Lancet, 2014
- Adverse events in IBD: to stop or continue immune suppressant and biologic treatmentExpert Review of Gastroenterology & Hepatology, 2014
- A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitisGut, 2012
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytesBritish Journal of Pharmacology, 2011
- Female gender and surgery impair relationships, body image, and sexuality in inflammatory bowel diseaseInflammatory Bowel Diseases, 2009